Cardiac spectroscopy: Techniques, indications and clinical results

European Radiology

Volumn 14, Issue 6, 2004, Pages 1034-1047

  Beer, Meinrad ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Absolute quantification; Fatty acids; Heart; Heart, failure; Heart, hypertrophy; Heart, involvement; Heart, ischemia; High energy phosphates; Magnetic resonance; Metabolism; MR spectroscopy; State of art reviews

Indexed keywords

PHOSPHORUS 31; PROTON;

CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; EXPERIMENTATION; HEALTH CARE FACILITY; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE METABOLISM; HUMAN; IMAGE DISPLAY; IMAGE PROCESSING; ISCHEMIC HEART DISEASE; MAGNETIC FIELD; MEDICAL ASSESSMENT; MEDICAL EXPERT; MULTIPLE SCLEROSIS; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBESITY; OUTCOMES RESEARCH; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; REVIEW;

CARDIOMYOPATHIES; CORONARY DISEASE; DIABETES MELLITUS; HEART FAILURE, CONGESTIVE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MULTIPLE SCLEROSIS; MYOCARDIUM; OBESITY;

EID: 2942700161     PISSN: 09387994     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00330-004-2279-3     Document Type: Review

References (92)

1. 31P nuclear magnetic resonance. J Physiol 258:82P
2. Jacobus W, Taylor G, Hollis D (1977) Phosphorus nuclear magnetic resonance of perfused rat hearts. Nature 265:756-758
3. Cardiac MR (2000) Spectroscopy. In: Pohost GM (ed) Imaging in cardiovascular disease. Lippincott, Philadelphia, PA; Williams & Wilkins, Baltimore
4. Neubauer S (1999) High-energy phosphate metabolism in normal, hypertrophied and failing human myocardium. Heart Fail Rev 4:269-280
5. Ingwall JS, Kramer MF, Fifer MA et al (1985) The creatine kinase system in normal and diseased myocardium. N Engl J Med 313:1050-1054
6. Wallimann T (1994) Dissecting the role of creatine kinase. Curr Biol 1:42-46
7. 1H-MR spectroscopy of the human heart. Magn Reson Med 42:903-910
8. 1H magnetic resonance spectroscopic imaging. Magn Reson Med 32:175-180
9. Henriksen O (1994) MR spectroscopy in clinical research. Acta Radiol 35:96-113
10. Bottomley PA (1994) MR spectroscopy of the human heart: The status and the challenges. Radiology 191:593-612
11. 31P NMR spectroscopy. Science 229:769-772
12. 31P-MR spectroscopy: SLOOP and clinical applications. J Magn Reson Imaging 13:521-527
13. 31P Spectroscopy. Magn Reson Med 48:380-384
14. Noogle JH, Schirmer RE (1971) The nuclear Overhauser effect. Academic, New York
15. Bottomley PA, Hardy CJ Proton (1992) Overhauser enhancements in human cardiac phosphorus NMR spectroscopy at 1.5 T. Magn Reson Med 24:384-390
16. De Roos A, Doornsbos J, Luyten PR, Oosterwaal LJMP, van der Wall EE, den Hollander JA (1992) Cardiac metabolism in patients with dilated and hypertrophied cardiomyopathy: assessment with proton-decoupled P-31 MR spectroscopy. J Magn Reson Imaging 2:711-719
17. 31P NMR spectroscopy detects metabolic abnormalities in asymptomatic patients with hypertrophic cardiomyopathy. Circulation 97:2536-2542
18. Mareci TH, Brooker HR (1984) High-resolution magnetic resonance spectra from a sensitive region defined with pulsed field gradients. J Magn Reson 57:157-163
19. 31P spectroscopic imaging with improved sensitifity, resolution and side lobe suppression. J Magn Reson B 104:85-88
20. Pohmann R, von Kienlin M (2001) Accurate phosphorus metabolite images of the human heart by 3D acquisition-weighted CSI. Magn Reson Med 45:817-826
21. 31P-Spektroskopie aller Wandabschnitte des Herzens mit akquistion-sgewichteter chemical shift Bildgebung. Fortschr Rö ntgenstr 173:1093-1098
22. Vanhamme L, van den Boogaart A, van Huffel S (1997) Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J Magn Reson 129:35-43
23. 31P-SLOOP-magnetic resonance spectroscopy. J Am Coll Cardiol 40:1267-1274
24. Bottomley PA, Hardy CJ, Roemer PB (1990) Phosphate metabolite imaging and concentration measurements in human heart by nuclear magnetic resonance. Magn Reson Med 14:425-434
25. 31P magnetic resonance spectroscopy. Circulation 92:15-23
26. Bottomley PA, Atalar E, Weiss RG (1996) Human cardiac high-energy phosphate metabolite concentrations by 1D-resolved NMR spectroscopy. Magn Reson Med 35:664-670
27. 31P-MRS. Magn Reson Med 39:772-782
28. 31P NMR spectroscopy. Magn Reson Med 39:679-685
29. Von Kienlin M, Mejia R (1991) Spectral localization with optimal pointspread function. Magn Reson Med 94:268-287
30. 31P MRS in humans. J Magn Reson 134:287-299
31. 31P-MR-spectroscopy and SLOOP in healthy and diseased myocardium. Rofo Fortschr Geb Roentgenstr Neuen Bildgeb Verfahr 171:65-68
32. 1 values. Magn Reson Med 32:137-141
33. 31P-NMR spectroscopy of human blood and serum: results from volunteers and patients with congestive heart failure, diabetes mellitus and hyperlipidemia. MAGMA 1:55-60
34. 31P NMR spectra for partial saturation: evidence that saturation factors for PCr/ATP are homogenous in normal and diseased states. J Magn Reson 95:341-355
35. De Roos A, Doornbos J, Luyten PR, Oosterwaal LJMP, van der Wall EE, den Hollander JA (1992) Cardiac metabolism in patients with dilated and hypertrophic cardiomyopathy. J Magn Reson Imaging 2:711-719
36. Hardy C, Weiss RG, Bottomley PA, Gerstenblith G (1991) Altered myocardial high-energy phosphate metabolites in patients with dilated cardiomyopathy. Am Heart J 122:795-801
37. 31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Circulation 86:1810-1818
38. Swain JL, Sabina RL, Peyton RB, Jones RN, Wechsler AS, Holmes EW (1982) Derangements in myocardial purine and pyrimidine nucleotide metabolism in patients with coronary artery disease and left ventricular hypertrophy. Proc Natl Acad Sci USA 79:655-659
39. Pluim BM, Lamb HJ, Kayser HWM et al (1998) Functional and metabolic evaluation of the athelet's heart by magnetic resonance imaging and dobutamine stress magnetic resonance spectroscopy. Circulation 97:666-672
40. Lamb HJ, Beyerbracht HP, van der Laarse A et al (1999) Diastolic function in hypertensive heart disease is associated with altered myocardial metabolism. Circulation 99:2261-2267
41. Auffermann W, Chew W, Wolfe CL, Tavares NJ, Parmley WW, Semelka RC, Donnelly T, Chatterjee K, Higgins CB (1991) Normal and diffusely abnormal myocardium in humans: functional and metabolic characterization with P-31 MR spectroscopy and cine MR imaging. Radiology 179:253-259
42. 31P magnetic resonance spectroscopy. Lancet 338:973-976
43. Beyerbacht HP, Lamb HJ, van der Laarse A, Vliegen HW, Leujes F, Hazekamp MG, de Roos A, van der Wall EE (2001) Aortic valve replacement in patients with aortic valve stenosis improves myocardial metabolism and diastolic function. Radiology 219:637-643
44. Lamb HJ, Beyerbacht HP, de Roos A, van der Laarse A, Vliegen HW, Leujes F, Bax JJ, van der Wall EE (2002) Left ventricular remodeling early after aortic valve replacement: differential effects on diastolic function in aortic valve stenosis and aortic regurgitation. J Am Coll Cardiol 40:2182-2188
45. 31P NMR spectroscopy detects metabolic abnormalities in asymptomatic patients with hypertrophic cardiomyopathy. Circulation 97:2536-2542
46. 31P-MRS. Magn Reson Med 39:772-782
47. McKenna WJ, Camm AJ (1989) Sudden death in hypertrophic cardiomyopathy: assessment of patients at high risk. Circulation 80:1489-1492
48. Drory Y, Turetz Y, Hiss Y, Lev B, Fisman EZ, Pines A, Kramer MR (1991) Sudden un expected death in persons <40 years of age. Am J Cardiol 68:1388-1392
49. 31P nuclear magnetic resonance spectroscopy: improvement after acute verapamil therapy. Circ Res 59:597-604
50. Camacho SA, Wikman-Coffelt J, Wu ST et al (1988) Improvement in myocardial performance without a decrease in high-energy phosphate metabolites after isoproterenol in Syrian cardiomyopathic hamsters. Circulation 77:712-719
51. Neubauer S (1998) Influence of LV pressures and heart rate on myocardial high-energy phosphate metabolism. Basic Res Cardiol 93 [Suppl 1]:102-107
52. 31P-MR-Spektroskopie. Radiologe 40:162-167
53. Spindler M, Saupe KW, Christe ME et al (1998) Diastolic dysfunction and altered energetics in the alphaMHC 403/+mouse model of the familial hypertrophic cardiomyopathy. J Clin Invest 101:1775-1783
54. Perrone-Filardi P, Bacharach SL, Dilsizian V, Panza JA, Maurera S, Bonow RO (1993) Regional systolic function, myocardial blood flow and glucose uptake at rest in hypertrophic cardiomyopathy. Am J Cardiol 72:199-204
55. 31P-magnetic resonance spectroscopy to the understanding of dilated heart muscle disease. Eur Heart J 16 [Suppl 0]: 115-118
56. 31P-MR-spectroscopy. Circulation 102 [Suppl 18]:678-679
57. Neubauer S, Horn M, Cramer M, Harre K, Newell JB, Peters W, Pabst T, Ertl G, Hahn D, Ingwall JS, Kochsiek K (1997) Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 96:2190-2196
58. Neubauer S, Horn M, Naumann A, Tian R, Hu K, Laser M, Friedrich J, Gaudron P, Schnackerz K, Ingwall JS (1995) Impairment of energy metabolism in intact residual myocardium of rat hearts with chronic myocardial infarction. J Clin Invest 95:1092-1100
59. Neubauer S (2002) Magnetresonanzspektroskopie des Herzens. In: Nagel E, van Rossum AC, Fleck E (eds) Kardiovaskuläre Magnetresonanztomographie. Steinkopff, Darmstadt, pp 181-190
60. Weiss RG, Bottomley PA, Hardy CJ, Gerstenblith (1990) Regional myocardial metabolism of high-energy phosphates during isometric exercise in patients with coronary artery disease. N Engl J Med 323:1593-1600
61. 31P magnetic resonance spectroscopy during handgrip exercise. Circulation 99:1709-1716
62. 31P magnetic resonance spectroscopic imaging of regional high-energy phosphate metabolism in injured rat heart. Magn Reson Med 39:731-741
63. 31P-MRS of human myocardial scar (abstract). Proc Soc Magnetic Resonance Med: 1091
64. 31P-MR-spectroscopy in humans. Eur Radiol 10:1323-1328
65. Bottomley PA, Weiss RG (1998) Non-invasive magnetic-resonance detection of creatine depletion in nonviable infarcted myocardium. Lancet 351:714-718
66. 1H-NMR visibility of creatine in isolated rat hearts. Magn Reson Med 43:497-502
67. 31P MRS study. Circulation 94:1089-1099
68. Epstein FH, Yang Z, Gilson WD, Berr SS, Kramer CM, French BA (2002) MR tagging early after myocardial infarction in mice demonstrates contractile dysfunction in adjacent and remote regions. Magn Reson Med 48:399-403
69. Greenberg MA, Grose RM, Neuburger N, Silverman R, Strain JE, Cohen MV (1987) Impaired vasodilator responsiveness as a cause of lactate production during pacing-induced ischemia in patients with agina pectoris and normal coronary arteries. J Am Coll Cardiol 9:743-751
70. Buchthal S, den Hollander JA, Noel C et al (2000) Abnormal myocardial phosphorus-31 nuclear magnetic resonance spectroscopy in women with chest pain but normal coronary angiograms. N Engl J Med 342:829-835
71. Hasdai D, Gibbons RJ, Holmes DR Jr, Higano ST, Lerman A (1997) Coronary endothelial dysfunction in humans is associated with myocardial perfusion defects. Circulation 96:3390-3395
72. Perloff JK, Stevenson WG, Roberts NK, Cabeen W, Weiss J (1984) Cardiac involvement in myotonic muscular dystrophy (Steinert's disease): a prospective study of 25 patients. Am J Cardiol 54:1074-1081
73. Stöllberger C, Finsterer J, Keller H, Mamoli B, Slany J (1998) Progression of cardiac involvement in patients with myotonic dystrophy, Becker's muscular dystrophy and mitochondrial myopahty during a 2-year follow-up. Cardiology 90:173-179
74. Perloff JK, Henze E, Schelbert HR (1984) Alterations in regional myocardial metabolism, perfusion and wall motion in Duchenne muscular dystrophy studied by radionuclide imaging. Circulation 69:33-42
75. 31P magnetic resonance spectroscopy study. Brain 120:1699-1711
76. Tarnopolsky MA, Parise G (1999) Direct measurement of high-energy phosphate compounds in patients with neuromuscular disease. Muscle Nerve 22:1228-1233
77. Ricker K (1999) Myotonic dystrophy and proximal myotonic myopathy. J Neurol 246:334-338
78. Pelargonio G, Dello Russo A, Sanna T, DeMartino G, Bellocci F (2002) Myotonic dystrophy and the heart. Heart 88:665-670
79. Lutsch G, Vetter R, Offhauss U, Wieske M, Grone HJ, Klemenz R, Schimke I, Stahl J, Benndorf R (1997) Abundance and location of the small heat shock proteins HSP25 and alphaB-crystallin in rat and human heart. Circulation 96:3466-3476
80. Parker TG, Marks A, Tsoporis JN (1998) Induction of S100b in myocardium: an intrinsic inhibitor of cardiac hypertrophy. Can J Appl Physiol 23:377-389
81. Koch-Henricksen N, Bronnum-Hansen H, Stenager E (1998) Underlying cause of death in Danish patients with multiple sclerosis: results from the Danish multiple sclerosis registry. J Neurol Neurosurg Psychiatry 65:56-59
82. Fleming ST, Blake RL Jr (1994) Patterns of comorbidity in elderly patients with multiple sclerosis. J Clin Epidemiol 47:1127-1132
83. 31P-MR-Spectroscopy and MRI study. Fortschr Röntgenstr 173:399-404
84. Stuart-Harris R, Pearson M, Smith IE, Olsen EG (1984) Cardiotoxicity associated with mitoxantrone [letter]. Lancet 2:219-220
85. Stammler J, Vaccaro O, Neaton JD, Wentworth D (1993) Diabetes, other risk factors and 12-year CVD mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 16:434-444
86. Scheuermann-Freestone M, Madsen PL, Manners D, Blamire AM, Buckingham RE, Styles P, Radda GK, Neubauer S, Clarke C (2003) Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. Circulation 107:3040-3046
87. Diamant M, Lamb H, Groeneveld Y, Endert EL, Smit JWA, Bax JJ, Romijn JA, de Roos A, Radder JK (2003) Diastolic dysfunction is associated with altered myocardial metabolism in asymtomatic normotensive patients with well-controlled type 2 diabetes mellitus. J Am Coll Cardiol 42:328-335
88. Zhou YT, Garyburn P, Karim A, Shimabukuro M, Higa M, Baetens D, Orci L, Unger RH (2000) Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci USA 97:1784-1789
89. Szczepaniak LS, Dobbins RL, Metzger GJ, Sartoni-D'Ambrosia G, Arbique D, Vongpatanasin W, Unger R, Victor RG (2003) Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magn Reson Med 49:417-423
90. Hunter JJ, Chien KR (1999) Signaling pathways for cardiac hypertrophy and failure. N Engl J Med 341:1276-1283
91. 31P chemical shift imaging of the human heart in a clinical setting: 1.5 T vs. 2.0 T. Proceedings of the ISMRM (abstract)
92. 31P-MR-Spektroskopie und MRT Studie. Fortschr Röntgenstr 174 [Suppl 41:286